Astute Medical
Astute Inks Deal With Shanghai Fosun for Chinese Distribution of NephroCheck, $20M in Financing
Premium
Astute is working with Fosun on Chinese trials for the test that it will use to gather data for a submission to the Chinese Food and Drug Administration.
The company has no plans to position NephroCheck for long-term prognosis but said the findings bolster data supporting use of the test in the acute setting.
From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.
NEW YORK (GenomeWeb) – With the recent clearance by the US Food and Drug Administration of its NephroCheck test for acute kidney injury, Astute Medical has achieved a milestone under the terms of its loan agreement with CRG which releases from CRG up to $30 million to support commercialization of
NEW YORK (GenomeWeb) – Astute Medical said this week that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.
Oct 19, 2012
Jun 8, 2012
Mar 11, 2011
Mar 8, 2011
Astute Medical Completes $13M Financing
May 14, 2010